Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity
Evotec AG today announced a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity as well as co morbidities such as nonalcoholic steatohepatitis (“NASH”), cardiovascular diseases, and diabetic kidney disease.
3 September 2019
Healthcare Business Summit (Portugal)
28 June 2019
Deep Dive in Hannover
19 June 2019
WHINN 2019 (Odense)